Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Drake

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Blood|October 21, 2016
MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adultsCorinna La Rosa, Jeff Longmate, Joy Martinez, et al.
The Lancet. Haematology|February 9, 2016
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialRyotaro Nakamura, Corinna La Rosa, Jeffrey Longmate, et al.
The Journal of Infectious Diseases|March 10, 2012
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvantCorinna La Rosa, Jeff Longmate, Simon F Lacey, et al.
Iscience|July 18, 2022
Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variantsFlavia Chiuppesi, John A Zaia, Katelyn Faircloth, et al.
Haematologica|February 8, 2024
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplantRyotaro Nakamura, Corinna La Rosa, Dongyun Yang, et al.
The Lancet. Microbe|March 15, 2022
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trialFlavia Chiuppesi, John A Zaia, Paul H Frankel, et al.
Vaccines|September 28, 2023
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular TherapyFlavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Blood|October 21, 2016
MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adultsCorinna La Rosa, Jeff Longmate, Joy Martinez, et al.
The Lancet. Haematology|February 9, 2016
Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trialRyotaro Nakamura, Corinna La Rosa, Jeffrey Longmate, et al.
The Journal of Infectious Diseases|March 10, 2012
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvantCorinna La Rosa, Jeff Longmate, Simon F Lacey, et al.
Iscience|July 18, 2022
Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variantsFlavia Chiuppesi, John A Zaia, Katelyn Faircloth, et al.
Haematologica|February 8, 2024
A phase II randomized, placebo-controlled, multicenter trial to evaluate the efficacy of cytomegalovirus PepVax vaccine in preventing cytomegalovirus reactivation and disease after allogeneic hematopoietic stem cell transplantRyotaro Nakamura, Corinna La Rosa, Dongyun Yang, et al.
The Lancet. Microbe|March 15, 2022
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trialFlavia Chiuppesi, John A Zaia, Paul H Frankel, et al.
Vaccines|September 28, 2023
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular TherapyFlavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, et al.
Pageof 5